High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability

References

• Massimino M, Stella S, Tirro E, et al. ABL1-directed inhibitors for CML: efficacy, resistance and future perspectives. Anticancer Res. 2020;40(5):2457–2465. doi:10.21873/anticanres.14215
   PubMed Web of Science ®Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172–183. doi:10.1038/nrc1567
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of bcr-abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant abl kinase domain mutants. Cancer Res. 2005;65(11):4500–4505. doi:10.1158/0008-5472.CAN-05-0259
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14(3):141–154. doi:10.1038/nrclinonc.2016.139
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401. doi:10.1126/science.1099480
   PubMed Web of Science ®Google Scholar
• Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298–305. doi:10.1200/JCO.2016.68.2914
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Shah NP. NCCN guidelines updates: discontinuing TKI therapy in the treatment of chronic myeloid leukemia. J Natl Compr Canc Netw. 2019;17(5.5):611–613. doi:10.6004/jnccn.2019.5013
   PubMed Web of Science ®Google Scholar
• Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65(19):8912–8919. doi:10.1158/0008-5472.CAN-05-0076
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876–880. doi:10.1126/science.1062538
   PubMed Web of Science ®Google Scholar
• Jiang X, Forrest D, Nicolini F, et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 2010;116(12):2112–2121. doi:10.1182/blood-2009-05-222471
   PubMed Web of Science ®Google Scholar
• Keeshan K, Mills KI, Cotter TG, McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia. 2001;15(12):1823–1833. doi:10.1038/sj.leu.2402309
   PubMed Web of Science ®Google Scholar
• Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119(2):530–539. doi:10.1182/blood-2010-08-303495
   PubMed Web of Science ®Google Scholar
• Modi H, McDonald T, Chu S, Yee J-K, Forman SJ, Bhatia R. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood. 2007;109(12):5411–5421. doi:10.1182/blood-2006-06-032490
   PubMed Web of Science ®Google Scholar
• Vigneri P, Stagno F, Stella S, et al. High BCR–ABL/GUSIS levels at diagnosis of chronic Phase CML are associated with unfavorable responses to standard-dose imatinib. Clin Cancer Res. 2017;23(23):7189–7198. doi:10.1158/1078-0432.CCR-17-0962
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–147. doi:10.1126/science.284.5411.143
   PubMed Web of Science ®Google Scholar
• Massimino M, Tirro E, Stella S, et al. Impact of the breakpoint region on the leukemogenic potential and the TKI responsiveness of atypical BCR-ABL1 transcripts. Front Pharmacol. 2021;12:669469. doi:10.3389/fphar.2021.669469
   PubMed Web of Science ®Google Scholar
• Muller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22(1):96–102. doi:10.1038/sj.leu.2404983
   PubMed Web of Science ®Google Scholar
• Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332–2338. doi:10.1182/blood-2006-02-004580
   PubMed Web of Science ®Google Scholar
• Buffa P, Romano C, Pandini A, et al. BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. FASEB J. 2014;28(3):1221–1236. doi:10.1096/fj.13-236992
   PubMed Web of Science ®Google Scholar
• Yang M, Xi Q, Jia W, Wang X. Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants. Bioorg Med Chem Lett. 2019;29(24):126758. doi:10.1016/j.bmcl.2019.126758
   PubMed Web of Science ®Google Scholar
• Saussele S, Haverkamp W, Lang F, et al. Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with focus on cardiovascular management. Acta Haematol. 2020;143(3):217–231. doi:10.1159/000501927
   PubMed Web of Science ®Google Scholar
• Ponchio L, Duma L, Oliviero B, Gibelli N, Pedrazzoli P, Robustelli Della Cuna G. Mitomycin C as an alternative to irradiation to inhibit the feeder layer growth in long-term culture assays. Cytotherapy. 2000;2(4):281–286. doi:10.1080/146532400539215
   PubMed Web of Science ®Google Scholar
• Konig H, Holtz M, Modi H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 2008;22(4):748–755. doi:10.1038/sj.leu.2405086
   PubMed Web of Science ®Google Scholar
• Liu M, Miller CL, Eaves CJ. Human long-term culture initiating cell assay. Methods Mol Biol. 2013;946:241–256.
   PubMedGoogle Scholar
• Massimino M, Vigneri P, Stella S, et al. Combined inhibition of Bcl2 and Bcr-Abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells. J Clin Med. 2021;10(23):5606. doi:10.3390/jcm10235606
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532–4539. doi:10.1182/blood-2005-07-2947
   PubMed Web of Science ®Google Scholar
• Primo D, Flores J, Quijano S, et al. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. Br J Haematol. 2006;135(1):43–51. doi:10.1111/j.1365-2141.2006.06265.x
   PubMed Web of Science ®Google Scholar
• Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003;12(1):27–37. doi:10.1016/S1097-2765(03)00274-0
   PubMed Web of Science ®Google Scholar
• Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396–409. doi:10.1172/JCI35721
   PubMed Web of Science ®Google Scholar
• Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18(4):930–937. doi:10.1158/1078-0432.CCR-10-1613
   PubMed Web of Science ®Google Scholar
• Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci U S A. 1992;89(13):6192–6196. doi:10.1073/pnas.89.13.6192
   PubMed Web of Science ®Google Scholar
• Eaves AC, Barnett MJ, Ponchio L, Cashman JD, Petzer AL, Eaves CJ. Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells. 1998;16(Suppl 1):77–83; discussion 9. doi:10.1002/stem.5530160809
   PubMedGoogle Scholar
• Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94(6):2056–2064. doi:10.1182/blood.V94.6.2056
   PubMed Web of Science ®Google Scholar
• Holyoake TL, Jiang X, Jorgensen HG, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood. 2001;97(3):720–728. doi:10.1182/blood.V97.3.720
   PubMed Web of Science ®Google Scholar
• Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005;24(42):6432–6440. doi:10.1038/sj.onc.1208796
   PubMed Web of Science ®Google Scholar
• Schemionek M, Elling C, Steidl U, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood. 2010;115(16):3185–3195. doi:10.1182/blood-2009-04-215376
   PubMed Web of Science ®Google Scholar
• Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657–667. doi:10.1056/NEJMoa040258
   PubMed Web of Science ®Google Scholar
• Burke BA, Carroll M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia. 2010;24(6):1105–1112. doi:10.1038/leu.2010.67
   PubMed Web of Science ®Google Scholar